SG11201702185UA - PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS - Google Patents

PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS

Info

Publication number
SG11201702185UA
SG11201702185UA SG11201702185UA SG11201702185UA SG11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA
Authority
SG
Singapore
Prior art keywords
intermediates
processes
preparation
c5ar antagonists
c5ar
Prior art date
Application number
SG11201702185UA
Other languages
English (en)
Inventor
Pingchen Fan
Jaroslaw Kalisiak
Antoni Krasinski
Rebecca Lui
Jay Powers
Sreenivas Punna
Hiroko Tanaka
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of SG11201702185UA publication Critical patent/SG11201702185UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201702185UA 2014-09-29 2015-09-28 PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS SG11201702185UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462057107P 2014-09-29 2014-09-29
PCT/US2015/052697 WO2016053890A1 (en) 2014-09-29 2015-09-28 PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS

Publications (1)

Publication Number Publication Date
SG11201702185UA true SG11201702185UA (en) 2017-04-27

Family

ID=55583729

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702185UA SG11201702185UA (en) 2014-09-29 2015-09-28 PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS

Country Status (19)

Country Link
US (5) US9745268B2 (es)
EP (2) EP3200791B1 (es)
JP (1) JP6898229B6 (es)
KR (2) KR102593431B1 (es)
CN (2) CN113121415A (es)
AU (2) AU2015324111B2 (es)
BR (1) BR112017006232B1 (es)
CA (2) CA3220371A1 (es)
DK (1) DK3200791T3 (es)
ES (2) ES2926828T3 (es)
IL (1) IL251061B (es)
MA (1) MA52308A (es)
MX (2) MX368492B (es)
NZ (2) NZ730123A (es)
PL (1) PL3200791T3 (es)
PT (1) PT3200791T (es)
RU (1) RU2712233C2 (es)
SG (1) SG11201702185UA (es)
WO (1) WO2016053890A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI465434B (zh) 2008-12-22 2014-12-21 Chemocentryx Inc Ｃ５ａＲ拮抗劑
CN103068385B (zh) * 2010-06-24 2015-04-29 凯莫森特里克斯股份有限公司 C5aR拮抗剂
SG11201702185UA (en) * 2014-09-29 2017-04-27 Chemocentryx Inc PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
BR112018014222A2 (pt) 2016-01-14 2018-12-11 Chemocentryx, Inc. método de tratamento da glomerulopatia c3
MA50537A (fr) * 2017-10-30 2021-04-07 Chemocentryx Inc Composés deutérés utilisés comme immunomodulateurs
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis
FI3886820T3 (fi) 2018-11-30 2023-05-25 Chemocentryx Inc Kapseliformulaatioita
KR102207333B1 (ko) * 2019-09-09 2021-01-27 성균관대학교산학협력단 4중 연속 고리 화합물의 신규한 제조방법
JP2023501789A (ja) * 2019-11-08 2023-01-19 ケモセントリックス，インコーポレイティド 補体成分Ｃ５ａ受容体の非晶質形態
CA3236256A1 (en) * 2019-11-08 2021-05-14 Chemocentryx, Inc. Salt forms of a complement component c5a receptor
KR20220098179A (ko) * 2019-11-08 2022-07-11 케모센트릭스, 인크. 보체 성분 C5a 수용체의 유리 염기 결정질 형태
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途
EP4137133A1 (en) 2021-08-19 2023-02-22 Sandoz AG Crystalline form of avacopan
WO2022263263A1 (en) 2021-06-16 2022-12-22 Sandoz Ag Crystalline form of avacopan
CN113957106B (zh) * 2021-11-03 2024-04-19 暨明医药科技（苏州）有限公司 一种Avacopan及其中间体的制备方法
CN114262291B (zh) * 2022-01-04 2023-05-19 重庆医科大学 一种阿伐可泮的合成方法
WO2023158722A2 (en) 2022-02-16 2023-08-24 Teva Pharmaceuticals International Gmbh Processes for preparation of avacopan and intermediates thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
RU2197288C2 (ru) 1999-08-03 2003-01-27 Тверская медицинская академия Способ лечения больных хроническим гломерулонефритом
WO2002049993A2 (en) 2000-09-29 2002-06-27 Neurogen Corporation High affinity small molecule c5a receptor modulators
JP2003532726A (ja) 2000-05-05 2003-11-05 スミスクライン・ビーチャム・コーポレイション 新規抗感染症薬
JP2004502672A (ja) * 2000-06-29 2004-01-29 アボット・ラボラトリーズ 細胞接着阻害抗炎症剤および免疫抑制剤としてのアリールフェニルシクロプロピルスルフィド誘導体およびその使用
JP5059275B2 (ja) 2000-08-10 2012-10-24 田辺三菱製薬株式会社 新規３置換尿素誘導体およびその医薬としての用途
KR100842791B1 (ko) 2000-09-14 2008-07-01 미쓰비시 타나베 파마 코퍼레이션 신규한 아미드 유도체 및 그의 의약적 용도
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
DE10293171D2 (de) 2001-07-19 2004-07-01 Luk Lamellen & Kupplungsbau Ausrücksystem zur Betätigung einer Kupplung eines Fahrzeuges
ATE360441T1 (de) 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
SI1427720T1 (sl) 2001-09-21 2009-08-31 Mitsubishi Tanabe Pharma Corp 3-substituirani-4-pirimidonski derivati
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
EP1487798A4 (en) 2002-03-28 2005-07-13 Neurogen Corp Substituted tetrahydroisoquinolines as C5A receptor modulators
WO2003084524A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US7138420B2 (en) 2002-08-08 2006-11-21 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
AU2003265625A1 (en) 2002-08-21 2004-03-11 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
AU2003290605A1 (en) 2002-11-05 2004-06-03 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004043925A2 (en) 2002-11-08 2004-05-27 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
EP1638935A1 (en) 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
WO2005007087A2 (en) 2003-07-03 2005-01-27 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EA200700117A1 (ru) 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CA2598423C (en) 2005-02-18 2014-05-27 Astrazeneca Ab Antibacterial piperidine derivatives
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
WO2007060215A2 (en) 2005-11-24 2007-05-31 Dompe' Pha.R.Ma S.P.A. (r)-arylkylamino derivatives and pharmaceutical compositions containing them
ES2612118T3 (es) 2006-03-15 2017-05-12 Alexion Pharmaceuticals, Inc. Tratamiento de pacientes de hemoglobinuria nocturna paroxística mediante un inhibidor del complemento
WO2008022060A2 (en) 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
EP2077842A2 (en) 2006-10-31 2009-07-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an egfr antagonist for the treatment of glomerolonephritis
WO2009004650A1 (en) 2007-06-29 2009-01-08 Torrent Pharmaceuticals Ltd. Novel substituted piperidones as hsp inducers
EP2331525A4 (en) 2008-08-11 2013-01-02 Harvard College HALOFUGINONE ANALOGUES FOR THE INHIBITION OF ARNT SYNTHÉTASES AND USES THEREOF
EP2331561A4 (en) 2008-09-03 2013-02-27 Xenome Ltd PEPTIDE CONJUGATE LIBRARIES AND METHODS OF MAKING SAME
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
PL2894165T3 (pl) 2008-11-10 2023-04-17 Alexion Pharmaceuticals, Inc. Sposoby i kompozycje do leczenia zaburzeń układu dopełniacza
TWI465434B (zh) 2008-12-22 2014-12-21 Chemocentryx Inc Ｃ５ａＲ拮抗劑
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
US20120252792A1 (en) 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
CN103068385B (zh) 2010-06-24 2015-04-29 凯莫森特里克斯股份有限公司 C5aR拮抗剂
AU2013277154A1 (en) 2012-06-20 2014-12-18 Jonathan E. Grob Complement pathway modulators and uses thereof
CN105392803B (zh) 2013-05-08 2019-12-06 诺和诺德股份有限公司 C5aR拮抗剂的用途
SG11201702185UA (en) 2014-09-29 2017-04-27 Chemocentryx Inc PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
BR112018014222A2 (pt) 2016-01-14 2018-12-11 Chemocentryx, Inc. método de tratamento da glomerulopatia c3
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
MX2023007420A (es) 2020-12-21 2023-06-29 Chemocentryx Inc Tratamiento de glomerulopatia c3 usando un inhibidor de c5a.

Also Published As

Publication number Publication date
IL251061A0 (en) 2017-04-30
BR112017006232A2 (pt) 2017-12-12
KR102593431B1 (ko) 2023-10-23
PT3200791T (pt) 2020-05-06
BR112017006232B1 (pt) 2022-10-11
NZ730123A (en) 2023-05-26
EP3682879A1 (en) 2020-07-22
CN106999481A (zh) 2017-08-01
US20200354320A1 (en) 2020-11-12
KR20170085492A (ko) 2017-07-24
MX2017003789A (es) 2017-08-02
RU2017114960A3 (es) 2019-04-10
JP6898229B6 (ja) 2021-07-28
MX368492B (es) 2019-10-04
EP3200791A4 (en) 2018-06-13
CN113121415A (zh) 2021-07-16
DK3200791T3 (da) 2020-05-25
JP2017529378A (ja) 2017-10-05
ES2926828T3 (es) 2022-10-28
WO2016053890A1 (en) 2016-04-07
KR20230149873A (ko) 2023-10-27
CA2960733A1 (en) 2016-04-07
NZ767823A (en) 2023-05-26
MX2019011911A (es) 2019-11-25
US9745268B2 (en) 2017-08-29
EP3200791A1 (en) 2017-08-09
AU2015324111A1 (en) 2017-04-06
JP6898229B2 (ja) 2021-07-07
ES2802428T3 (es) 2021-01-19
US10266492B2 (en) 2019-04-23
RU2017114960A (ru) 2018-11-07
CN106999481B (zh) 2021-04-16
US20180072668A1 (en) 2018-03-15
US20230008966A1 (en) 2023-01-12
CA3220371A1 (en) 2016-04-07
AU2015324111B2 (en) 2021-04-01
EP3682879B1 (en) 2022-08-03
US10532982B2 (en) 2020-01-14
MA52308A (fr) 2021-02-24
US11845729B2 (en) 2023-12-19
US20160090357A1 (en) 2016-03-31
US20190276402A1 (en) 2019-09-12
EP3200791B1 (en) 2020-04-22
IL251061B (en) 2019-09-26
RU2712233C2 (ru) 2020-01-27
PL3200791T3 (pl) 2020-08-10
AU2021204209A1 (en) 2021-07-15
CA2960733C (en) 2024-01-09
AU2021204209B2 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
IL251061B (en) Processes and building materials in the preparation of c5ar antagonists
IL279606A (en) Anti-TREM2 antibodies and methods of using them
HK1243102A1 (zh) 抗cd79b抗體和使用方法
IL250415B (en) Antibodies against pd-l and methods of using them
HRP20181359T1 (hr) Anti-jagged1 protutijela i postupci uporabe
IL251868A0 (en) Anti-tim3 antibodies and methods of use
GB201421847D0 (en) Dispensers and methods of use thereof
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
IL247754A0 (en) Antibodies against mcam and related methods of use
IL247315B (en) Anti-acth antibodies and their uses
HK1250146A1 (zh) 抗前-bcr拮抗劑和方法
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use
ZA201604870B (en) Recombinant microorganisms and methods of use thereof
HK1246288A1 (zh) S1pr2拮抗劑及其用途
IL247448A0 (en) Peptides and methods of use
GB201509977D0 (en) Dispensers and methods of use thereof
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201404133D0 (en) Garment and method of use thereof